Literature DB >> 7885247

Reversibility of muscle and heart lesions in chronic, Trypanosoma cruzi infected mice after late trypanomicidal treatment.

M A Segura1, E Molina de Raspi, M A Basombrio.   

Abstract

The effect of trypanomicidal treatment upon established histopathological Trypanosoma cruzi induced lesions was studied in Swiss mice. The animals were inoculated with 50 trypomastigotes and infection was allowed to progress without treatment for 99 days. After this period, the animals were divided in three groups, treated for 30 days with either placebo, benznidazole (200 mg/kg/day) or nifurtimox (100 mg/kg/day). These treatments induced 94 and 100% cure rates respectively as detected by xenodiagnosis and reduction of antibody levels. Autopsies and histopathological studies of heart, urinary bladder and skeletal muscle performed on day 312 after infection showed almost complete healing without residual lesions. As long periods were allowed between infection, treatment and autopsy, the results indicate that tissue lesions depend, up to advances stages, on the continuous presence of the parasite.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7885247     DOI: 10.1590/s0074-02761994000200017

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  13 in total

1.  Low-Level Parasite Persistence Drives Vasculitis and Myositis in Skeletal Muscle of Mice Chronically Infected with Trypanosoma cruzi.

Authors:  Joseph D Weaver; Victoria J Hoffman; Ester Roffe; Philip M Murphy
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

2.  Influence of acute-phase parasite load on pathology, parasitism, and activation of the immune system at the late chronic phase of Chagas' disease.

Authors:  C R Marinho; M R D'Império Lima; M G Grisotto; J M Alvarez
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

3.  Combination Therapy Using Benznidazole and Aspirin during the Acute Phase of Experimental Chagas Disease Prevents Cardiovascular Dysfunction and Decreases Typical Cardiac Lesions in the Chronic Phase.

Authors:  Rito Santo Pereira; Aparecida Donizette Malvezi; Maria Isabel Lovo-Martins; Bruno Fernando Cruz Lucchetti; Jussevania Pereira Santos; Eliandro Reis Tavares; Waldiceu Aparecido Verri; Eduardo José de Almeida Araújo; Lucy Megumi Yamauchi; Sueli Fumie Yamada-Ogatta; Marli Cardoso Martins-Pinge; Phileno Pinge-Filho
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

4.  Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.

Authors:  Simone Garcia; Carolina O Ramos; Juliana F V Senra; Fabio Vilas-Boas; Maurício M Rodrigues; Antonio C Campos-de-Carvalho; Ricardo Ribeiro-Dos-Santos; Milena B P Soares
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+ T-cell expansion and promotes resistance to reinfection.

Authors:  Bianca Perdigão Olivieri; Vinícius Cotta-De-Almeida; Tania Araújo-Jorge
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

6.  Pharmacokinetics and Tissue Distribution of Benznidazole after Oral Administration in Mice.

Authors:  Luísa Perin; Rodrigo Moreira da Silva; Kátia da Silva Fonseca; Jamille Mirelle de Oliveira Cardoso; Fernando Augusto Siqueira Mathias; Levi Eduardo Soares Reis; Israel Molina; Rodrigo Correa-Oliveira; Paula Melo de Abreu Vieira; Cláudia Martins Carneiro
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 7.  Chagas' heart disease.

Authors:  A Rassi; A Rassi; W C Little
Journal:  Clin Cardiol       Date:  2000-12       Impact factor: 2.882

8.  Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions.

Authors:  Ivo Santana Caldas; André Talvani; Sérgio Caldas; Cláudia Martins Carneiro; Marta de Lana; Paulo Marcos da Matta Guedes; Maria Terezinha Bahia
Journal:  Parasitol Res       Date:  2008-05-04       Impact factor: 2.289

9.  Chemotherapy of chronic indeterminate Chagas disease: a novel approach to treatment.

Authors:  Paola Carolina Bazán; María Silvina Lo Presti; Héctor Walter Rivarola; María Fernanda Triquell; Ricardo Fretes; Alicia Ruth Fernández; Julio Enders; Patricia Paglini-Oliva
Journal:  Parasitol Res       Date:  2008-05-31       Impact factor: 2.289

10.  A serological, parasitological and clinical evaluation of untreated Chagas disease patients and those treated with benznidazole before and thirteen years after intervention.

Authors:  Girley Francisco Machado-de-Assis; Glaucia Alessio Diniz; Roberto Araújo Montoya; João Carlos Pinto Dias; José Rodrigues Coura; George Luiz Lins Machado-Coelho; Pedro Albajar-Viñas; Rosália Morais Torres; Marta de Lana
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-11       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.